Related Experiment Video
Updated: May 10, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice
Ana Muñiz-Lozano1, Fabiana Rollini, Francesco Franchi
1University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA. dominick.angiolillo@jax. ufl.edu
Abstract:
Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndrome (ACS) and undergoing percutaneous coronary intervention (PCI). Glycoprotein IIb/IIIa receptors mediate platelet aggregation, representing the final common pathway of platelet-mediated thrombosis. Therefore, agents blocking this pathway may be desirable for the treatment of patients with ACS and PCI. Glycoprotein IIb/IIIa receptor inhibitors have been widely investigated and have been key to the pharmacological advancements in the field. However, although GPIs have been important to reduce ischemic complications, their elevated risk of bleeding complications remains a major limitation. The poor prognostic implications, including increased mortality, associated with bleeding complication underscores the need for alternative treatment options. Over the past years there have been several advancements in antithrombotic pharmacology which have led to changes in recommendations for GPI usage in clinical practice. This is an overview of the most recent clinical trial data on GPIs, and provides practical insight on their modern day use in ACS therapy.
Insights
Glycoprotein IIb/IIIa inhibitors reduce ischemic events in acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) but increase bleeding risk. Newer antithrombotic options are emerging, impacting clinical practice guidelines for GPI use.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Antiplatelet therapy is crucial for acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).
- Glycoprotein IIb/IIIa (GPI) receptors are central to platelet aggregation and thrombosis.
- GPI inhibitors have advanced ACS treatment but carry a significant bleeding risk.
Purpose of the Study:
- To review recent clinical trial data on GPI inhibitors in ACS therapy.
- To provide practical insights into the current use of GPIs.
- To address the limitations of GPIs, particularly bleeding risk, and explore alternatives.
Main Methods:
- Review of recent clinical trial data on Glycoprotein IIb/IIIa inhibitors.
- Analysis of antithrombotic pharmacology advancements.
- Evaluation of changes in clinical practice recommendations for GPI usage.
Main Results:
- GPI inhibitors effectively reduce ischemic complications in ACS and PCI.
- A major limitation of GPIs is their associated increased risk of bleeding complications.
- Advancements in antithrombotic pharmacology are shifting clinical practice regarding GPI use.
Conclusions:
- Despite benefits in reducing ischemic events, the bleeding risk of GPIs necessitates careful consideration.
- The prognostic impact of bleeding complications highlights the need for alternative antithrombotic strategies.
- Evolving antithrombotic options are reshaping the modern use of GPIs in ACS management.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...